Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Jaguar Health Inc (JAGX)
Jaguar Health Inc (JAGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Jaguar Health Inc 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104 USA

https://jaguar.health P: 415-371-8300

Description:

Jaguar Health, Inc. is a natural-products pharmaceuticals company. It focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals. The company through its subsidiary Napo Pharmaceuticals Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals. Its product pipeline consists of Mytesi(R), Canalevia(TM), Equilevia(TM) and Neonorm (TM). Jaguar Health Inc., formerly known as Jaguar Animal Health Inc., is based in San Francisco, United States.

Key Statistics

Overview:

Market Capitalization, $K 16,242
Enterprise Value, $K 28,512
Shares Outstanding, K 50,756
Annual Sales, $ 11,960 K
Annual Net Income, $ -47,450 K
Last Quarter Sales, $ 2,810 K
Last Quarter Net Income, $ -7,780 K
EBIT, $ -33,030 K
EBITDA, $ -18,980 K
60-Month Beta 1.68
% of Insider Shareholders 0.16%
% of Institutional Shareholders 12.24%
Float, K 50,675
% Float 99.84%
Short Volume Ratio 0.48

Growth:

1-Year Return -96.60%
3-Year Return -99.63%
5-Year Return -99.99%
5-Year Revenue Growth 174.31%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.38 on 11/14/23
Next Earnings Date N/A
Earnings Per Share ttm -3.19
EPS Growth vs. Prev Qtr 9.52%
EPS Growth vs. Prev Year 95.79%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-75 on 01/23/23

JAGX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -1,191.67%
Return-on-Assets % -79.95%
Profit Margin % -396.74%
Net Margin % N/A
Debt/Equity 21.94
Price/Sales 1.38
Price/Cash Flow N/A
Price/Book 6.83
Book Value/Share 0.06
Interest Coverage -2.81
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar